72088 Federal Register / Vol. 88, No. 201 / Thursday, October 19, 2023 / Notices 

SUMMARY: In compliance with the 

requirement of the Paperwork 

Reduction Act of 1995, the Office of the 

Secretary (OS), Department of Health 

and Human Services, is publishing the 

following summary of a proposed 

collection for public comment. 

DATES: Comments on the ICR must be 

received on or before November 20, 

2023. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain . Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. 

FOR FURTHER INFORMATION CONTACT: 

Sagal Musa, sagal.musa@hhs.gov or 

(202) 205–2634. When submitting 

comments or requesting information, 

please include the document identifier 

4040–0010–30D and project title for 

reference. 

SUPPLEMENTARY INFORMATION: Interested 

persons are invited to send comments 

regarding this burden estimate or any 

other aspect of this collection of 

information, including any of the 

following subjects: (1) The necessity and 

utility of the proposed information 

collection for the proper performance of 

the agency’s functions; (2) the accuracy 

of the estimated burden; (3) ways to 

enhance the quality, utility, and clarity 

of the information to be collected; and 

(4) the use of automated collection 

techniques or other forms of information 

technology to minimize the information 

collection burden. 

Title of the Collections: Project/ 

Performance Site Location(s), Project 

Abstract, and Key Contacts forms. 

Type of Collection: Revision. 

OMB No. 4040–0010. 

Abstract: The Project/Performance 

Site Location(s), Project Abstract, and 

Key Contacts forms provide the Federal 

grant-making agencies an alternative to 

the Standard Form 424 data set and 

form. Agencies may use Project/ 

Performance Site Location(s), Project 

Abstract, and Key Contacts forms for 

grant programs not required to collect 

all the data that is required on the SF– 

424 core data set and form. 

Type of respondent: Project/ 

Performance Site Location(s), Project 

Abstract, and Key Contacts forms are 

used by organizations to apply for 

Federal financial assistance in the form 

of grants. This form is submitted to the 

Federal grant-making agencies for 

evaluation and review. Previously, 26 

Federal grant-making entities were 

using this information collection. This 

information collection will now be 

utilized by 51 Federal grant-making 

agencies and additional grant-making 

entities. To improve the transparency of 

reading and enhance user-friendliness 

of the supporting statement A, language 

modifications were implemented within 

sections 3 through 16. For section 14, 

Cost to the Federal Government was 

adjusted to the 2023 base general 

schedule.Grants.gov is requesting a 

revision of this collection to allow for 

data reporting and publication by 

agencies requesting to use the common 

form. The information collection (IC) 

expires on November 30, 2025. 

Grants.gov seeks a three-year clearance 

of these collections. 

ANNUALIZED BURDEN HOUR TABLE

Forms 

(if necessary) 

Respondents 

(if necessary) Number of respondents 

Number of 

responses per 

respondents 

Average 

burden per 

response 

Total burden hours 

Project/performance site 

location(s).

Grant Applicants ............. 127,281 ........................... 1 1 127,281 

Project Abstract ............... Grant Applicants ............. 230 .................................. 1 1 230 

Key Contacts ................... Grant Applicants ............. 4,566 ............................... 1 1 4,566 

Total .......................... ......................................... 132,077 ........................... 1 1 132,077 

Sherrette A. Funn, 

Paperwork Reduction Act Reports Clearance 

Officer, Office of the Secretary. 

[FR Doc. 2023–23074 Filed 10–18–23; 8:45 am] 

BILLING CODE 4151–AE–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive Patent 

Commercialization License: Human 

Monoclonal Antibodies That Broadly 

Target Coronaviruses 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Institute of 

Allergy and Infectious Diseases, an 

institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an exclusive patent license to 

Leyden Laboratories B.V., located at 

Emmy Noetherweg 2, 2333 BK Leiden, 

the Netherlands to practice the 

inventions embodied in the patent 

applications listed in the 

SUPPLEMENTARY INFORMATION section of 

this notice. 

DATES: Only written comments and/or 

applications for a license which are 

received by the Technology Transfer 

and Intellectual Property Office, 

National Institute of Allergy and 

Infectious Diseases on or before 

November 3, 2023 will be considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, and 

comments relating to the contemplated 

exclusive patent license should be 

directed to: Dawn Taylor-Mulneix, 

Technology Transfer and Patent 

Specialist, Technology Transfer and 

Intellectual Property Office, National 

Institute of Allergy and Infectious 

Diseases, 5601 Fishers Lane, Suite 2G, 

MSC 9804, Rockville, MD 20852–9804, 

phone number 301–767–5189, or 

dawn.taylor-mulneix@nih.gov. 

SUPPLEMENTARY INFORMATION: The 

following represents the intellectual 

property to be licensed under the 

prospective agreement: U.S. provisional 

application (63/308,898), filed on 

February 19, 2022, and the PCT 

application (PCT/US2023/062324), filed 

on February 9, 2023, entitled ‘‘Human 

Monoclonal Antibodies that Broadly 

Target Coronaviruses’’ (HHS Reference 

No. E–047–2022). All rights in these 

inventions have been assigned to the 

Government of the United States of 

America. 

The prospective exclusive patent 

commercialization license territory may 

be worldwide, and the field of use may 

be limited to: Prevention and treatment 

of coronavirus infection, illness, and 

transmission through mucosal delivery 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 88, No. 201 / Thursday, October 19, 2023 / Notices 72089 

to the respiratory tract of products, 

comprised of COV44–62 (fusion 

peptide), COV44–79 (fusion peptide), 

COV89–22 (stem helix), and/or COV72– 

37 (stem helix), including products that 

may be obtained from the genetic 

sequence of the same and derivatives 

thereof. The prospective exclusive 

patent commercialization license may 

include two products (preventative and 

therapeutic) in the field of use. 

An abstract for this invention was 

published in the Federal Register on 

June 10, 2022. The family of 

coronaviruses cause upper respiratory 

tract disease in humans and have 

caused three major disease outbreaks in 

recent history: the 2003 SARS outbreak, 

the 2012 MERS outbreak, and the 

current SARS–CoV–2 pandemic. There 

is an urgent need for strategies that 

broadly target coronaviruses, both to 

deal with new SARS–CoV–2 variants 

and future coronavirus outbreaks. 

Scientists at NIAID have developed 

several novel human monoclonal 

antibodies that bind to conserved parts 

of the SARS–CoV–2 spike protein. 

These antibodies can neutralize SARS– 

CoV–2 variants of concern including 

Omicron BA.1 and BA.2, as well as 

neutralize at least one other 

betacoronavirus. Further, these 

antibodies limit disease in animal 

models. Broadly reactive antibodies 

against coronaviruses are useful tools to 

identify conserved sites on the 

coronavirus spike protein, which could 

be investigated for the development of 

broad coronavirus vaccines that aim to 

prevent future pandemics. Potent 

neutralizers that target these sites could 

also be useful for prevention of disease 

caused by diverse coronaviruses, 

including those that may emerge in the 

future. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive patent 

commercialization license will be 

royalty bearing, and may be granted 

unless within fifteen (15) days from the 

date of this published notice, the 

National Institute of Allergy and 

Infectious Diseases receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

Complete applications for a license in 

the prospective field of use that are 

timely filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive patent 

commercialization license. Comments 

and objections submitted in response to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 522. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2023–23030 Filed 10–18–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No. USCG–2023–0823] 

National Maritime Security Advisory 

Committee; December 2023 Virtual 

Meeting 

AGENCY: U.S. Coast Guard, Department 

of Homeland Security. 

ACTION: Notice of Federal advisory 

committee virtual meeting. 

SUMMARY: The National Maritime 

Security Advisory Committee 

(Committee) will conduct a virtual 

meeting to discuss the Committee’s final 

recommendations concerning ways to 

enhance cyber security information 

sharing between the U. S. Coast Guard 

and Marine Transportation System 

(MTS) stakeholders. The virtual meeting 

will be open to the public. 

DATES: Meeting: The Committee will 

meet virtually on Tuesday, December 5, 

2023, from 1 p.m. until 3 p.m. Eastern 

Standard Time (EST). Please note this 

virtual meeting may close early if the 

Committee has completed its business. 

Comments and supporting 

documentation: To ensure your 

comments are received by Committee 

members before the virtual meeting, 

submit your written comments no later 

than December 1, 2023. 

ADDRESSES: To join the virtual meeting 

or to request special accommodations, 

contact the individual listed in the FOR

FURTHER INFORMATION CONTACT section 

no later than 1 p.m. EST on December 

4, 2023, to obtain the needed 

information. The number of virtual lines 

are limited and will be available on a 

first-come, first-served basis. 

Pre-registration information: Preregistration is required for attending the 

virtual meeting. You must request 

attendance by contacting the individual 

listed in the FOR FURTHER INFORMATION

CONTACT section below. You will receive 

a response with attendance instructions. 

The National Maritime Security 

Advisory Committee is committed to 

ensuring all participants have equal 

access regardless of disability status. If 

you require reasonable accommodations 

due to a disability to fully participate, 

please email Mr. Ryan Owens at 

ryan.f.owens.uscg.mil or call (202) 302– 

6565 as soon as possible. 

Instructions: You are free to submit 

comments at any time, including orally 

at the meeting as time permits, But, if 

you want Committee members to review 

your comment before the meeting, 

please submit your comments no later 

than December 1, 2023. We are 

particularly interested in comments 

regarding the topics in the ‘‘Agenda’’ 

section below. We encourage you to 

submit comments through the Federal 

Decision Making Portal at https://

www.regulations.gov. To do so, go to 

https://www.regulations.gov, type 

USCG–2023–0823 in the search box and 

click ‘‘Search’’. Next, look for this 

document in the Search Results column, 

and click on it. Then click on the 

Comment option. If your material 

cannot be submitted using https://

www.regulations.gov, contact the 

individual in the FOR FURTHER

INFORMATION CONTACT section for 

alternate instructions. You must include 

the docket number USCG–2023–0823. 

Comments received will be posted 

without alteration at https://

www.regulations.gov including any 

personal information provided. You 

may wish to review the Privacy and 

Security Notice found via a link on the 

homepage https://www.regulations.gov. 

For more about the privacy and 

submissions in response to this 

document, see DHS’s eRulemaking 

System of Records notice (85 FR 14226, 

March 11, 2020). If you encounter 

technical difficulties with comment 

submission, contact the individual 

listed in the FOR FURTHER INFORMATION

CONTACT section of this notice. 

Docket Search: Documents mentioned 

in this notice as being available in the 

docket, and all public comments, will 

be in our online docket at https://

www.regulations.gov, and can be viewed 

by following that website’s instructions. 

Additionally, if you go to the online 

docket and sign-up for email alerts, you 

will be notified when comments are 

posted. 

FOR FURTHER INFORMATION CONTACT: Mr. 

Ryan Owens, Alternate Designated 

Federal Officer of the National Maritime 

Security Advisory Committee, 2703 

Martin Luther King Jr. Avenue SE, 

Washington, DC 20593, Stop 7581, 

Washington, DC 20593–7581; telephone 

202–302–6565 or via email at 

ryan.f.owens@uscg.mil. 

SUPPLEMENTARY INFORMATION: Notice of 

this meeting is in compliance with the 

Federal Advisory Committee Act, (Pub. 

L. 117–286, 5 U.S.C., ch. 10). The 


lotter on DSK11XQN23PROD with NOTICES1